Coronavirus disease 2019

Last updated

Coronavirus disease 2019
Other names
  • 2019-nCoV acute respiratory disease
  • Novel coronavirus pneumonia [1]
  • Wuhan pneumonia [2] [3]
  • Wuhan coronavirus
  • "Coronavirus" or other names for SARS-CoV-2
Symptoms of coronavirus disease 2019 2.0.svg
Symptoms of COVID-19
Specialty Infectious diseases
SymptomsFever, cough, shortness of breath [4]
Complications Pneumonia, viral sepsis, acute respiratory distress syndrome, kidney failure
Usual onset Incubation period typically 5-6 days (may range between 2-14 days)
Causes Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Risk factors Travel, viral exposure
Diagnostic method rRT-PCR testing, CT scan
Prevention Hand washing, quarantine, physical distancing
Treatment Symptomatic and supportive
Frequency657,898 confirmed cases [5]
Deaths30,433 deaths (4.6% of confirmed cases) [5]

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). [6] The disease was first identified in 2019 in Wuhan, the capital of China's Hubei province, and has since spread globally, resulting in the ongoing 2019–2020 coronavirus pandemic. [7] [8] Common symptoms include fever, cough, and shortness of breath. [9] Other symptoms may include muscle pain, sputum production, diarrhea, sore throat, loss of smell, and abdominal pain. [4] [10] [11] While the majority of cases result in mild symptoms, some progress to pneumonia and multi-organ failure. [7] [12] As of March 28, 2020, the overall rate of deaths per number of diagnosed cases is 4.6 percent; ranging from 0.2 percent to 15 percent according to age group and other health problems. [5]


The virus is mainly spread during close contact and via respiratory droplets produced when people cough or sneeze. [13] [14] Respiratory droplets may be produced during breathing but the virus is not considered airborne. [15] [13] People can also contract COVID-19 by touching a contaminated surface and then their face. [13] [14] It is most contagious when people are symptomatic, although spread may be possible before symptoms appear. [14] The virus can live on surfaces up to 72 hours. [16] Time from exposure to onset of symptoms is generally between two and fourteen days, with an average of five days. [9] [17] The standard method of diagnosis is by reverse transcription polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab. [18] The infection can also be diagnosed from a combination of symptoms, risk factors and a chest CT scan showing features of pneumonia. [19] [20]

Recommended measures to prevent infection include frequent hand washing, social distancing (maintaining physical distance from others, especially from those with symptoms), covering coughs and sneezes with a tissue or inner elbow, and keeping unwashed hands away from the face. [21] [22] The use of masks is recommended by some national health authorities for those who suspect they have the virus and their caregivers, but not for the general public, although simple cloth masks may be used by those who desire them. [23] [24] There is no vaccine or specific antiviral treatment for COVID-19. Management involves treatment of symptoms, supportive care, isolation, and experimental measures. [25]

The World Health Organization (WHO) declared the 2019–20 coronavirus outbreak a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 [26] [27] and a pandemic on 11 March 2020. [8] Local transmission of the disease has been recorded in many countries across all six WHO regions. [28]

Signs and symptoms

Symptom [29] %
Dry cough67.7
Sputum production33.4
Loss of smell 15 [30] to 30 [11] [31]
Shortness of breath18.6
Muscle or joint pain 14.8
Sore throat13.9
Nausea or vomiting5.0
Nasal congestion4.8
Diarrhoea 3.7 to 31 [32]
Haemoptysis 0.9
Conjunctival congestion0.8

Those infected with the virus may be asymptomatic or develop flu-like symptoms, including fever, cough, fatigue, and shortness of breath. [4] [33] [34] Emergency symptoms include difficulty breathing, persistent chest pain or pressure, confusion, difficulty waking, and bluish face or lips; immediate medical attention is advised if these symptoms are present. [35] Less commonly, upper respiratory symptoms, such as sneezing, runny nose, or sore throat may be seen. Symptoms such as nausea, vomiting, and diarrhea have been observed in varying percentages. [32] [36] [37] Some cases in China initially presented only with chest tightness and palpitations. [38] In March 2020 there were reports indicating that loss of the sense of smell (anosmia) may be a common symptom among those who have mild disease, [11] [31] although not as common as initially reported. [30] In some, the disease may progress to pneumonia, multi-organ failure, and death. [7] [12] In those who develop severe symptoms, time from symptom onset to needing mechanical ventilation is typically 8 days. [39]

As is common with infections, there is a delay between the moment when a person is infected with the virus and the time when they develop symptoms. This is called the incubation period. The incubation period for COVID-19 is typically five to six days but may range from two to 14 days. [40] [41] 97.5% of people who develop symptoms will do so within 11.5 days of infection. [42]


The disease is caused by the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously referred to as the 2019 novel coronavirus (2019-nCoV). [43] It is primarily spread between people via respiratory droplets from coughs and sneezes. [44] A study investigating the rate of decay of the virus found no viable viruses after four hours on copper, 24 hours on cardboard, 72 hours on stainless steel, and 72 hours on plastic. However, detection rates did not reach 100% and varied between surface type (limit of detection was 3.33×100.5 TCID50 per liter of air for aerosols, 100.5 TCID50 per milliliter of medium for plastic, steel, and cardboard, and 101.5 TCID50 per milliliter of medium for copper). Estimation of the rate of decay with a Bayesian regression model suggests that viruses may remain viable up to 18 hours on copper, 55 hours on cardboard, 90 hours on stainless steel, and over 100 hours on plastic. The virus remained viable in aerosols throughout the time of the experiment (three hours). [45] The virus has also been found in faeces, and transmission through faeces is being researched. [46] [47]

The lungs are the organs most affected by COVID-19 because the virus accesses host cells via the enzyme ACE2, which is most abundant in the type II alveolar cells of the lungs. The virus uses a special surface glycoprotein called a "spike" (peplomer) to connect to ACE2 and enter the host cell. [48] The density of ACE2 in each tissue correlates with the severity of the disease in that tissue and some have suggested that decreasing ACE2 activity might be protective, [49] [50] though another view is that increasing ACE2 using angiotensin II receptor blocker medications could be protective and that these hypotheses need to be tested. [51] As the alveolar disease progresses, respiratory failure might develop and death may follow. [50]

The virus also affects gastrointestinal organs as ACE2 is abundantly expressed in the glandular cells of gastric, duodenal and rectal epithelium [46] as well as endothelial cells and enterocytes of the small intestine. [52] The virus has been found in the faeces of as many as 53% [46] of hospitalised people and more anal swab positives have been found than oral swab positives in the later stages of infection. [53] The virus was found in faeces from 1 to 12 days and 17% of patients continued to present the virus in faeces after no longer presenting them in respiratory samples, indicating that the viral gastrointestinal infection and the potential fecal-oral transmission can last even after viral clearance in the respiratory tract. [46] Reoccurrence of the virus has also been detected through anal swabs suggesting a shift from more oral positive during the early stages of the disease to more anal positive during later periods. [53]

The virus is thought to be natural and have an animal origin, [54] [55] through spillover infection. [56] The origin is unknown but by December 2019 the spread of infection was almost entirely driven by human-to-human transmission. [57] [58] The earliest known infection occurred on 17 November 2019 in Wuhan, China. [59]


CDC rRT-PCR test kit for COVID-19 CDC 2019-nCoV Laboratory Test Kit.jpg
CDC rRT-PCR test kit for COVID-19

The WHO has published several testing protocols for the disease. [61] The standard method of testing is real-time reverse transcription polymerase chain reaction (rRT-PCR). [62] The test is typically done on respiratory samples obtained by a nasopharyngeal swab, however a nasal swab or sputum sample may also be used. [18] [63] Results are generally available within a few hours to two days. [64] [65] Blood tests can be used, but these require two blood samples taken two weeks apart and the results have little immediate value. [66] Chinese scientists were able to isolate a strain of the coronavirus and publish the genetic sequence so that laboratories across the world could independently develop polymerase chain reaction (PCR) tests to detect infection by the virus. [7] [67] [68] As of 19 March 2020, [69] there were no antibody tests though efforts to develop them are ongoing. [70] The FDA approved the first point-of-care test on 21 March 2020 for use at the end of that month. [71]

Diagnostic guidelines released by Zhongnan Hospital of Wuhan University suggested methods for detecting infections based upon clinical features and epidemiological risk. These involved identifying people who had at least two of the following symptoms in addition to a history of travel to Wuhan or contact with other infected people: fever, imaging features of pneumonia, normal or reduced white blood cell count, or reduced lymphocyte count. [19]

A March 2020 review concluded that chest Xrays are of little value in early stages, whereas CT scans of the chest are useful even before symptom occur. [72] Typical features on CT include bilateral multilobar ground-glass opacificities with a peripheral, asymmetric and posterior distribution. [72] Subpleural dominance, crazy paving and consolidation develop as the disease evolves. [73] As of March 2020, the American College of Radiology recommends that "CT should not be used to screen for or as a first-line test to diagnose COVID-19". [74]


Few data are available about microscope lesions and pathophysiology of COVID-19. [75] Main pathological findings at autopsy are :


An illustration of the effect of spreading out infections over a long period of time, known as flattening the curve; decreasing peaks allows healthcare services to better manage the same volume of patients. Covid-19-curves-graphic-social-v3.gif
An illustration of the effect of spreading out infections over a long period of time, known as flattening the curve; decreasing peaks allows healthcare services to better manage the same volume of patients.
Alternatives to flattening the curve Covid-19-curves-graphic2-stopthespread-v3.gif
Alternatives to flattening the curve

Preventive measures to reduce the chances of infection include staying at home, avoiding crowded places, washing hands with soap and warm water often and for at least 20 seconds, practicing good respiratory hygiene and avoiding touching the eyes, nose, or mouth with unwashed hands. [81] [82] [83] The CDC recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available. [81] They also recommend proper hand hygiene after any cough or sneeze. [81] Social distancing strategies aim to reduce contact of infected persons with large groups by closing schools and workplaces, restricting travel, and canceling mass gatherings. [84] Social distancing also includes that people stay at least 6 feet apart (about 1.80 meters). [85]

Because a vaccine against SARS-CoV-2 is not expected to become available until 2021 at the earliest, [86] a key part of managing the COVID-19 pandemic is trying to decrease the epidemic peak, known as flattening the epidemic curve through various measures seeking to reduce the rate of new infections. [77] Slowing the infection rate helps decrease the risk of health services being overwhelmed, allowing for better treatment of current cases, and delaying additional cases until therapeutics or a vaccine become available. [77]

According to the WHO, the use of masks is recommended only if a person is coughing or sneezing or when one is taking care of someone with a suspected infection. [87] Some countries also recommend healthy individuals to wear face masks, particularly China, [88] Hong Kong [89] and Thailand. [90] In order to meet the need for masks, the WHO estimates that global production will need to increase by 40%. Hoarding and speculation have worsened the problem, with the price of masks increasing sixfold, N95 respirators tripled, and gowns doubled. [91] Some health experts consider wearing non-medical-grade masks and other face coverings like scarves or bandanas a good way to prevent people from touching their mouths and noses, even if non-medical coverings would not protect against a direct sneeze or cough from an infected person. [92]

Those diagnosed with COVID-19 or who believe they may be infected are advised by the CDC to stay home except to get medical care, call ahead before visiting a healthcare provider, wear a face mask before entering the healthcare provider's office and when in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water, and avoid sharing personal household items. [93] [94] The CDC also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose, coughing, or sneezing. It further recommends using an alcohol-based hand sanitizer with at least 60% alcohol, but only when soap and water are not readily available. [81]

For areas where commercial hand sanitizers are not readily available, WHO provides two formulations for local production. In these formulations, the antimicrobial activity arises from ethanol or isopropanol. Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis". Glycerol is added as a humectant. [95]


Four steps to putting on personal protective equipment DonningCDC2020.jpg
Four steps to putting on personal protective equipment

People are managed with supportive care, which may include fluid, oxygen support, and supporting other affected vital organs. [97] [98] [99] The CDC recommends that those who suspect they carry the virus wear a simple face mask. [23] Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration. [100] [101]

The WHO and Chinese National Health Commission have published recommendations for taking care of people who are hospitalised with COVID-19. [102] [103] Intensivists and pulmonologists in the US have compiled treatment recommendations from various agencies into a free resource, the IBCC. [104] [105]


While the WHO does not oppose the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen for symptoms, [106] some recommend paracetamol (acetaminophen) for first-line use. [107] [108] There are four reported cases of children who developed severe symptoms after taking ibuprofen. [109] The FDA states that currently there is no evidence that NSAIDs worsen COVID-19 symptoms. [110]

While theoretical concerns have been raised about ACE inhibitors and angiotensin receptor blockers, as of 19 March 2020, these are not sufficient to justify stopping these medications. [111] [112] [113] Steroids such as methylprednisolone are not recommended unless the disease is complicated by acute respiratory distress syndrome. [114] [115]

Personal protective equipment

Precautions must be taken to minimize the risk of virus transmission, especially in healthcare settings when performing procedures that can generate aerosols, such as intubation or hand ventilation. [116]

CDC outlines the specific guidelines for the use of personal protective equipment (PPE) during the pandemic. The recommended gear includes:

When available, respirators (instead of facemasks) are preferred. [122] N95 respirators are approved for industrial settings but the FDA has authorized the masks for use under an Emergency Use Authorization (EUA). They are designed to protect from airborne particles like dust but effectiveness against a specific biological agent is not guaranteed for off-label uses. [123] When masks are not available the CDC recommends using face shields, or as a last resort homemade masks. [124]

Mechanical ventilation

Most cases of COVID-19 are not severe enough to require mechanical ventilation (artificial assistance to support breathing), but a percentage of cases do. [125] [126] Some Canadian doctors recommend the use of invasive mechanical ventilation because this technique limits the spread of aerosolized transmission vectors. [125] Severe cases are most common in older adults (those older than 60 years [125] and especially those older than 80 years [127] ). Many developed countries do not have enough hospital beds per capita, which limits a health system's capacity to handle a sudden spike in the number of COVID-19 cases severe enough to require hospitalization. [128] This limited capacity is a significant driver of the need to flatten the curve (to keep the speed at which new cases occur and thus the number of people sick at one point in time lower). [128] One study in China found 5% were admitted to intensive care units, 2.3% needed mechanical support of ventilation, and 1.4% died. [100] Every ventilator is worth its weight in gold as a source says a third of all Coronavirus patients could need it. [129] A number of organizations are using 3D printing to produce various needed equipment. [130]

Acute respiratory distress syndrome

Mechanical ventilation becomes more complex as ARDS develops in COVID-19 and oxygenation becomes more difficult [131] . Ventilators capable of pressure control modes and high PEEP [132] (often unavailable on older and transport ventilators) are needed to maximize oxygen delivery while minimizing the risk of ventilator-associated lung injury and pneumothorax [133] .

Options for ARDS [131]
High-flow nasal oxygen For SpO2 <93%. May prevent the need for intubation and ventilation
Tidal volume 6mL per kg and can be reduced to 4mL/kg
Plateau airway pressure Keep below 30 cmH2O if possible (high respiratory rate (35 per minute) may be required)
Positive end-expiratory pressure Moderate to high levels
Prone positioning For worsening oxygenation
Inhaled nitrous oxide 5-20 ppm
Fluid management Goal is a negative balance of 1/2-1L per day
Antibiotics For secondary bacterial infections
Glucocorticoids Not recommended

Experimental treatment

No medications are approved to treat the disease by the WHO although some are recommended by individual national medical authorities. [134] Research into potential treatments started in January 2020, [135] and several antiviral drugs are in clinical trials. [136] [137] Although new medications may take until 2021 to develop, [138] several of the medications being tested are already approved for other uses, or are already in advanced testing. [134] Antiviral medication may be tried in people with severe disease. [97] The WHO recommended volunteers take part in trials of the effectiveness and safety of potential treatments. [139]

Information technology

In February 2020, China launched a mobile app to deal with the disease outbreak. [140] Users are asked to enter their name and ID number. The app is able to detect 'close contact' using surveillance data and therefore a potential risk of infection. Every user can also check the status of three other users. If a potential risk is detected, the app not only recommends self-quarantine, it also alerts local health officials. [141]

Big data analytics on cellphone data, facial recognition technology, mobile phone tracking and artificial intelligence are used to track infected people and people whom they contacted in South Korea, Taiwan and Singapore. [142] [143] In March 2020, the Israeli government enabled security agencies to track mobile phone data of people supposed to have coronavirus. The measure was taken to enforce quarantine and protect those who may come into contact with infected citizens. [144] Also in March 2020, Deutsche Telekom shared aggregated phone location data with the German federal government agency, Robert Koch Institute, in order to research and prevent the spread of the virus. [145] Russia deployed facial recognition technology to detect quarantine breakers. [146] Italian regional health commissioner Giulio Gallera said that he has been informed by mobile phone operators that "40% of people are continuing to move around anyway". [147] German government conducted a 48 hours weekend hackathon with more than 42.000 participants. [148] [149] Also the president of Estonia, Kersti Kaljulaid, made a global call for creative solutions against the spread of coronavirus. [150]

Psychological support

Individuals may experience distress from quarantine, travel restrictions, side effects of treatment, or fear of the infection itself. To address these concerns, the National Health Commission of China published a national guideline for psychological crisis intervention on 27 January 2020. [151] [152]


The severity of diagnosed COVID-19 cases in China [153]
Illustration of SARS-COV-2 Case Fatality Rate 200228 01-1.png
Case fatality rates by age group in China. Data through 11 February 2020. [57]
Comorbidity and severity in covid-19 data from China CDC Weekly 2020, 2(8), pp. 113-122 (cropped).png
Case fatality rate in China depending on other health problems. Data through 11 February 2020. [57]
The number of deaths vs total cases by country and approximate case fatality rate

The severity of COVID-19 varies. The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold. Mild cases typically recover within two weeks, while those with severe or critical disease may take three to six weeks to recover. Among those who have died, the time from symptom onset to death has ranged from two to eight weeks. [29]

Children of all ages are susceptible to the disease, but are likely to have milder symptoms and a much lower chance of severe disease than adults; in those younger than 50 years, the risk of death is less than 0.5%, while in those older than 70 it is more than 8%. [154] [155] Pregnant women may be at higher risk for severe infection with COVID-19 based on data from other similar viruses, like SARS and MERS, but data for COVID-19 is lacking. [156] [157]

In some people, COVID-19 may affect the lungs causing pneumonia. In those most severely affected, COVID-19 may rapidly progress to acute respiratory distress syndrome (ARDS) causing respiratory failure, septic shock, or multi-organ failure. [158] [159] Complications associated with COVID-19 include sepsis, abnormal clotting, and damage to the heart, kidneys, and liver. Clotting abnormalities, specifically an increase in prothrombin time, have been described in 6% of those admitted to hospital with COVID-19, while abnormal kidney function is seen in 4% of this group. [160] Liver injury as shown by blood markers of liver damage is frequently seen in severe cases. [161]

Some studies have found that the neutrophil to lymphocyte ratio (NLR) may be helpful in early screening for severe illness. [162]

Many of those who die of COVID-19 have pre-existing (underlying) conditions, including hypertension, diabetes mellitus, and cardiovascular disease. [163] The Istituto Superiore di Sanità (ISS) reported that 88% of overall deaths in Italy had at least one comorbidity. [164] An additional report by the ISS reported that out of 10.4% of deaths where medical charts were available for review, there were at least one comorbidity in 97.9% of sampled patients with the average patient having 2.7 diseases. [165] According to the same report, the median time between onset of symptoms and death was nine days, with five being spent hospitalized. However, patients transferred to an ICU had a median time of six days between hospitalization and death. [165] In a study of early cases, the median time from exhibiting initial symptoms to death was 14 days, with a full range of six to 41 days. [166] In a study by the National Health Commission (NHC) of China, men had a death rate of 2.8% while women had a death rate of 1.7%. [167] Histopathological examinations of post-mortem lung samples show diffuse alveolar damage with cellular fibromyxoid exudates in both lungs. Viral cytopathic changes were observed in the pneumocytes. The lung picture resembled acute respiratory distress syndrome (ARDS). [29] In 11.8% of the deaths reported by the National Health Commission of China, heart damage was noted by elevated levels of troponin or cardiac arrest. [38]

Availability of medical resources and the socioeconomics of a region may also affect mortality. [168] Estimates of the mortality from the condition vary because of those regional differences, [169] but also because of methodological difficulties. The under-counting of mild cases can cause the mortality rate to be overestimated. [170] However, the fact that deaths are the result of cases contracted in the past can mean the current mortality rate is underestimated. [171] [172]

It is unknown if past infection provides effective and long-term immunity in people who recover from the disease. [173] Immunity is likely, based on the behaviour of other coronaviruses, [174] but cases in which recovery from COVID-19 have been followed by positive tests for coronavirus at a later date have been reported. [175] [176] It is unclear if these cases are the result of reinfection, relapse, or testing error.[ citation needed ]

Concerns have been raised about long-term sequelae of the disease. The Hong Kong Hospital Authority found a drop of 20% to 30% in lung capacity in some people who recovered from the disease, and lung scans suggested organ damage. [177]

Case fatality rates (%) by age and country
China as of 11 February [57]
Italy as of 26 March [164]
Netherlands as of 27 March [178]
South Korea as of 27 March [179]
Spain as of 26 March [180]
Case fatality rates (%) by age in the United States
United States as of 16 March [181] 0.00.1-0.20.5-0.81.4-2.62.7-4.94.3-10.510.4-27.3
Note: The lower bound includes all cases. The upper bound excludes cases that were missing data.


The case fatality rate (CFR) depends on the availability of healthcare, government measures/responses, the typical age and health problems within the population, and the number of undiagnosed cases. [182] [183] [184] Preliminary research has yielded case fatality rate numbers between 2% and 3%; [5] in January 2020, the WHO suggested that the case fatality rate was approximately 3%, [185] and 2% in February 2020 in Hubei. [186] Other CFR numbers, which adjust for differences in time of confirmation, death or remission but are not peer reviewed, are respectively 7% [187] and 33% for people in Wuhan 31 January. [188] An unreviewed preprint of 55 deaths noted that early estimates of mortality may be too high as asymptomatic infections are missed. They estimated a mean infection fatality ratio (IFR, the mortality among infected) ranging from 0.8% to 0.9%. [189] A peer-reviewed article published on 19 March estimated the overall symptomatic case fatality risk as 1.4% (IQR 0.9–2.1%). [190] The outbreak in 2019–2020 has caused at least 652,079 edit confirmed infections and 30,313 edit deaths. [191]

The epidemic spreads faster where people are close together and/or travel to other areas. Researchers found that travel restrictions can reduce the basic reproduction number from 2.35 to 1.05, allowing the epidemic to be manageable. [192]

An observational study of nine people found no vertical transmission from mother to the newborn. [193] Also, a descriptive study in Wuhan found no evidence of viral transmission through vaginal sex (from female to partner), but authors note that transmission during sex might occur through other routes. [194]


The World Health Organization announced in February 2020 that COVID-19 is the official name of the disease. World Health Organization chief Tedros Adhanom Ghebreyesus explained that CO stands for corona, VI for virus and D for disease, while 19 is for the year that the outbreak was first identified; 31 December 2019. [197] The name had been chosen to avoid references to a specific geographical location (i.e. China), animal species, or group of people, in line with international recommendations for naming aimed at preventing stigmatisation. [198] [199]

While the disease is named COVID-19, the virus that causes it is named severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2. [200] The virus was initially referred to as the 2019 novel coronavirus or 2019-nCoV. [201] The WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications. [200] Coronaviruses were named in 1968 for their appearance in electron micrographs which was reminiscent of the solar corona, corona meaning crown in Latin. [202] [203] [204]

In February 2020, the World Health Organization advised the public to not refer to Coronavirus as the "Chinese virus" or "Wuhan virus". [205] [206] [207] [208] Even more controversial terms, such as "Wuflu" and "Kung Flu", also emerged in the United States during this period (outside the community of medical professionals) as offensive ways of describing COVID-19. These terms are linked to Wuhan, where the virus (which is not a flu) was first detected, or China in general, via portmanteau with terms from traditional Chinese Martial Arts, Wushu and Kung Fu. Use of these terms, despite their playfulness, imply that the pandemic is China's aggressive gift to the world, when actually thousands of Chinese suffered and died from COVID-19, especially in Wuhan. [209] [210]


Because of its key role in the transmission and progression of SARS-CoV-2, ACE2 has been the focus of a significant proportion of research and various therapeutic approaches have been suggested. [50] Personal hygiene, and a healthy lifestyle and diet have been recommended to improve immunity. [211]


There is no available vaccine, but research into developing a vaccine has been undertaken by various agencies. Previous work on SARS-CoV is being utilised because SARS-CoV-2 and SARS-CoV both use the ACE2 receptor to enter human cells. [212] There are three vaccination strategies being investigated. First, researchers aim to build a whole virus vaccine. The use of such a virus, be it inactive or dead, aims to elicit a prompt immune response of the human body to a new infection with COVID-19. A second strategy, subunit vaccines, aims to create a vaccine that sensitises the immune system to certain subunits of the virus. In the case of SARS-CoV-2, such research focuses on the S-spike protein that helps the virus intrude the ACE2 enzyme receptor. A third strategy is that of the nucleic acid vaccines (DNA or RNA vaccines, a novel technique for creating a vaccination). Experimental vaccines from any of these strategies would have to be tested for safety and efficacy. [213]

On 16 March 2020, the first clinical trial of a vaccine started with four volunteers in Seattle. The vaccine contains a harmless genetic code copied from the virus that causes the disease. [214]


Several existing antiviral medications are being evaluated for treatment of COVID-19 and some have moved into clinical trials. [134] In March 2020, WHO launched a multi-country trial involving 10 countries called "Solidarity" in response to COVID-19 pandemic. Remdesivir, chloroquine and hydroxychloroquine, ritonavir/lopinavir and ritonavir/lopinavir combined with interferon beta are the experimental treatments currently being researched under Solidarity Trial. [215] [216]

There is tentative evidence for remdesivir as of March 2020. [217] Remdesivir inhibits SARS-CoV-2 in vitro . [218] Phase 3 clinical trials are being conducted in the US, in China, and in Italy. [134] [219] [220]

Chloroquine, previously used to treat malaria, was studied in China in February 2020, with positive preliminary results. [221] However, there are calls for peer review of the research. [222] The Guangdong Provincial Department of Science and Technology and the Guangdong Provincial Health and Health Commission issued a report stating that chloroquine phosphate "improves the success rate of treatment and shortens the length of person's hospital stay" and recommended it for people diagnosed with mild, moderate and severe cases of novel coronavirus pneumonia. [223]

On 17 March, the Italian Pharmaceutical Agency included chloroquine and hydroxychloroquine in the list of drugs with positive preliminary results for treatment of COVID-19. [224] Korean and Chinese Health Authorities recommend the use of chloroquine. [225] [226] However, the Wuhan Institute of Virology, while recommending a daily dose of one gram, notes that twice that dose is highly dangerous and could be lethal. As of 20 March 2020, the treatment has not yet been approved by the U.S. Food and Drug Administration. [227]

The Chinese 7th edition guidelines also include interferon, ribavirin, or umifenovir for use against COVID-19. [226]

In 2020, a trial found that lopinavir/ritonavir was ineffective in the treatment of severe illness. [228] Nitazoxanide has been recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2. [218]

Studies have demonstrated that initial spike protein priming by transmembrane protease serine 2 (TMPRSS2) is essential for entry of SARS-CoV-2 via interaction with the ACE2 receptor. [229] [230] These findings suggest that the TMPRSS2 inhibitor camostat approved for use in Japan for inhibiting fibrosis in liver and kidney disease might constitute an effective off-label treatment. [229]

In February 2020, favipiravir was being studied in China for experimental treatment of the emergent COVID-19 disease. [231] [232]

Anti-cytokine storm

Cytokine storm, a life-threatening medical condition, can be a complication in the later stages of severe COVID-19. There is evidence that hydroxychloroquine has anti-cytokine storm properties. [233]

Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed. [234] [235] It is undergoing a phase 2 non randomized test at the national level in Italy after showing positive results in people with severe disease. [224] [236] [237] [ unreliable medical source? ] Combined with a serum ferritin blood test to identify cytokine storms, it is meant to counter such developments, which are thought to be the cause of death in some affected people. [238] [239] [240] The interleukin-6 receptor antagonist was approved by the FDA for treatment against cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017. [241] [ unreliable medical source? ]

The Feinstein Institute of Northwell Health announced in March a study on "a human antibody that may prevent the activity" of IL-6. [242]

Passive antibody therapy

Transferring donated blood containing antibodies produced by the immune systems of those who have recovered from COVID-19 to people who need them is being investigated as a non vaccine method of immunization. [243] This strategy was tried for SARS. [243] Viral neutralization is the anticipated mechanism of action by which passive antibody therapy can mediate defense against SARS-CoV-2. Other mechanisms, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may however be possible. [243] Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development. [243] Production of 'convalescent serum', which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, could be increased for quicker deployment. [244]

See also

Related Research Articles

Severe acute respiratory syndrome Respiratory disease caused by the SARS coronavirus

Severe acute respiratory syndrome (SARS) is a viral respiratory disease of zoonotic origin that surfaced in the early 2000s caused by the first-identified strain of the SARS coronavirus. In late 2017, Chinese scientists traced the virus through the intermediary of civets to cave-dwelling horseshoe bats in Yunnan province. No cases of the first SARS-CoV have been reported worldwide since 2004.

Coronavirus Subfamily of viruses in the family Coronaviridae

Coronaviruses are a group of related viruses that cause diseases in mammals and birds. In humans, coronaviruses cause respiratory tract infections that can be mild, such as some cases of the common cold, and others that can be lethal, such as SARS, MERS, and COVID-19. Symptoms in other species vary: in chickens, they cause an upper respiratory tract disease, while in cows and pigs they cause diarrhea. There are yet to be vaccines or antiviral drugs to prevent or treat human coronavirus infections.

Viral pneumonia is a pneumonia caused by a virus. Viruses are one of the two major causes of pneumonia, the other being bacteria; less common causes are fungi and parasites. Viruses are the most common cause of pneumonia in children, while in adults bacteria are a more common cause.

Severe acute respiratory syndrome coronavirus virus strain causing severe acute respiratory syndrome

Severe acute respiratory syndrome coronavirus (SARS-CoV) is the strain of virus that causes severe acute respiratory syndrome (SARS). It is an enveloped, positive-sense, single-stranded RNA virus which infects the epithelial cells within the lungs. The virus enters the host cell by binding to the ACE2 receptor. It infects humans, bats, and palm civets.

Human coronavirus NL63 or HCoV-NL63 is a species of coronavirus that was identified in late 2004 in a seven-month-old child with bronchiolitis in the Netherlands. The infecting virus is an enveloped, positive-sense, single-stranded RNA virus which enters its host cell by the ACE2 receptor. Infection with the virus has been confirmed worldwide, and has an association with many common symptoms and diseases. Associated diseases include mild to moderate upper respiratory tract infections, severe lower respiratory tract infection, croup and bronchiolitis.

<i>Middle East respiratory syndrome-related coronavirus</i> species of virus

Middle East respiratory syndrome-related coronavirus (MERS-CoV), or EMC/2012 (HCoV-EMC/2012), is a species of coronavirus which infects humans, bats, and camels. The infecting virus is an enveloped, positive-sense, single-stranded RNA virus which enters its host cell by binding to the DPP4 receptor. The species is a member of the genus Betacoronavirus and subgenus Merbecovirus.

Middle East respiratory syndrome Viral respiratory infection

Middle East respiratory syndrome (MERS), also known as camel flu, is a viral respiratory infection caused by the MERS-coronavirus (MERS-CoV). Symptoms may range from mild to severe. They include fever, cough, diarrhea and shortness of breath. Disease is typically more severe in those with other health problems. Mortality is about one-third of diagnosed cases.

Favipiravir Experimental antiviral drug with activity against many RNA viruses.

Favipiravir, also known as T-705, Avigan, or favilavir is an antiviral drug being developed by Toyama Chemical of Japan with activity against many RNA viruses. Like certain other experimental antiviral drugs, it is a pyrazinecarboxamide derivative. In experiments conducted in animals Favipiravir has shown activity against influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Activity against enteroviruses and Rift Valley fever virus has also been demonstrated. Favipiravir has showed limited efficacy against Zika virus in animal studies, but was less effective than other antivirals such as MK-608. The agent has also shown some efficacy against rabies, and has been used experimentally in some humans infected with the virus.

Remdesivir Antiviral drug

Remdesivir is a novel antiviral drug in the class of nucleotide analogs. It was developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections, though it subsequently was found to show antiviral activity against other single stranded RNA viruses such as respiratory syncytial virus, Junin virus, Lassa fever virus, Nipah virus, Hendra virus, and the coronaviruses. It is being studied for SARS-CoV-2 and Henipavirus infections. Based on success against other coronavirus infections, Gilead provided remdesivir to physicians who treated an American patient in Snohomish County, Washington in 2020, who was infected with SARS-CoV-2, and is providing the compound to China to conduct a pair of trials in infected individuals with and without severe symptoms.

2019–20 coronavirus pandemic ongoing pandemic of coronavirus disease 2019 (COVID-19)

The 2019–20 coronavirus pandemic is an ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The outbreak was first identified in Wuhan, Hubei, China, in December 2019, and was recognized as a pandemic by the World Health Organization (WHO) on 11 March. As of 28 March 2020, more than 662,000 cases of COVID-19 have been reported in over 190 countries and territories, resulting in approximately 30,800 deaths. More than 141,000 people have since recovered.

Severe acute respiratory syndrome coronavirus 2 Virus strain causing coronavirus disease 2019

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known by the provisional name 2019 novel coronavirus (2019-nCoV), is a positive-sense single-stranded RNA virus. It is contagious in humans and is the cause of the ongoing pandemic of coronavirus disease 2019 (COVID-19) that was designated a Public Health Emergency of International Concern on 30 January 2020 by the World Health Organization (WHO), and a pandemic on 11 March 2020.

The Huanan Seafood Wholesale Market, also known as the Huanan Seafood Market, was a live animal and seafood market in Jianghan District, Wuhan, Hubei, China. The market gained media attention after being identified as a point of origin of the 2019–20 coronavirus pandemic. The World Health Organization was notified on 31 December 2019 about an outbreak of pneumonia in Wuhan. Of the initial 41 people hospitalized with pneumonia who were officially identified as having laboratory-confirmed SARS-CoV-2 infection by 2 January 2020, two-thirds were exposed to the market. The market was closed on 1 January 2020 for sanitary procedures and disinfection. 33 out of 585 environmental samples obtained from the market indicated evidence of coronavirus disease 2019 (COVID-19).

2020 coronavirus pandemic in Thailand Details of ongoing viral pandemic in Thailand

An outbreak of coronavirus disease 2019 (COVID-19), part of the 2019–2020 global pandemic, has been ongoing in Thailand since 13 January 2020, when the country made the first confirmation of a case outside China. Surveillance among incoming travellers revealed a small number of cases throughout January, almost all of whom were visitors or residents returning from China. The first reported local transmission was confirmed on 31 January. The number of cases remained low throughout February, with forty confirmed by the end of the month. Cases saw a sharp increase in mid-March, which was attributed to several transmission clusters, the largest of which occurred at a Muay Thai fight at the Lumpinee Boxing Stadium on 6 March. Confirmed cases rose to over a hundred per day over the following week, and public venues and businesses were ordered to close in Bangkok and several other provinces. Prime Minister Prayut Chan-o-cha declared a state of emergency, effective on 26 March, though a curfew has not been announced.

Laboratory testing for the respiratory coronavirus disease 2019 (COVID-19) and the associated SARS-CoV-2 virus includes methods that detect the presence of virus and those that detect antibodies produced in response to infection. Detection of antibodies (serology) can be used both for clinical purposes and population surveillance.

2020 coronavirus pandemic in Finland Details of ongoing viral pandemic in Finland

The 2020 coronavirus pandemic in Finland is an ongoing viral pandemic of coronavirus disease 2019 (COVID-19), a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case of COVID-19 in Finland during the 2019–20 worldwide pandemic was confirmed on 29 January 2020, when a Chinese tourist visiting Ivalo from Wuhan tested positive for the virus.

COVID-19 vaccine Hypothetical vaccine against COVID-19

A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine. In late February 2020, the World Health Organization (WHO) said it did not expect a vaccine against SARS-CoV-2, the causative virus, to become available in less than 18 months. By late March 2020, some 40 vaccine candidates were in development.

The effect of COVID-19 infection on pregnancy is not completely known because of the lack of reliable data. Findings from a small study in China shows that clinical characteristics of COVID-19 pneumonia in pregnant women were similar to those reported from non-pregnant adults. As of March 2020, there is no evidence for vertical transmission of COVID-19 from mother to child in late pregnancy. Predictions based on similar infections such as SARS and MERS suggest that pregnant women are at an increased risk of severe infection.

COVID-19 drug repurposing research Drug repurposing research related to COVID-19

Drug repositioning – the investigation of existing drugs for new therapeutic purposes – is one line of scientific research which is followed to develop safe and effective COVID-19 treatments. Other research directions include the development of a COVID-19 vaccine.

COVID-19 drug development Preventative vaccines and therapies for COVID-19 infection

COVID-19 drug development is the research process to develop a preventative vaccine or therapeutic prescription drug that would alleviate the severity of 2019-20 coronavirus disease (COVID-19). Internationally as of March 2020, some 100 drug companies, biotechnology firms, university research groups, and health organizations were involved in stages of vaccine or drug development. The World Health Organization (WHO), European Medicines Agency (EMA), US Food and Drug Administration (FDA), and the Chinese government and drug manufacturers were coordinating with academic and industry researchers to speed development of vaccines, antiviral drugs, and monoclonal antibody therapies.


  1. 国家卫生健康委关于新型冠状病毒肺炎暂命名事宜的通知 (in Chinese). National Health Commission. 7 February 2020. Archived from the original on 28 February 2020. Retrieved 9 February 2020.
  2. Campbell C (20 January 2020). "The Wuhan Pneumonia Crisis Highlights the Danger in China's Opaque Way of Doing Things". Time . Retrieved 13 March 2020.
  3. Lucey D, Sparrow A (14 January 2020). "China Deserves Some Credit for Its Handling of the Wuhan Pneumonia". Foreign Policy . Retrieved 13 March 2020.
  4. 1 2 3 "Coronavirus Disease 2019 (COVID-19) Symptoms". Centers for Disease Control and Prevention . United States. 10 February 2020. Archived from the original on 30 January 2020.
  5. 1 2 3 4 "Coronavirus (COVID-19) Mortality Rate". 5 March 2020. Retrieved 23 March 2020.
  6. "Naming the coronavirus disease (COVID-19) and the virus that causes it". World Health Organization (WHO). Archived from the original on 28 February 2020. Retrieved 28 February 2020.
  7. 1 2 3 4 Hui, D. S.; I. Azhar E.; Madani, T. A.; Ntoumi, F.; Kock, R.; Dar, O.; Ippolito, G.; Mchugh, T. D.; Memish, Z. A.; Drosten, Christian; Zumla, A.; Petersen, E. (February 2020). "The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China". Int J Infect Dis. 91: 264–66. doi: 10.1016/j.ijid.2020.01.009 . PMID   31953166.
  8. 1 2 "WHO Director-General's opening remarks at the media briefing on COVID-19". World Health Organization (WHO) (Press release). 11 March 2020. Retrieved 12 March 2020.
  9. 1 2 "Symptoms of Novel Coronavirus (2019-nCoV)". 10 February 2020. Archived from the original on 30 January 2020. Retrieved 11 February 2020.
  10. "Q&A on coronaviruses (COVID-19)". World Health Organization (WHO). Retrieved 11 March 2020.
  11. 1 2 3 Hopkins, Claire. "Loss of sense of smell as marker of COVID-19 infection". Ear, Nose and Throat surgery body of United Kingdom. Retrieved 28 March 2020.
  12. 1 2 "Q&A on coronaviruses". World Health Organization (WHO). Archived from the original on 20 January 2020. Retrieved 27 January 2020.
  13. 1 2 3 "Q&A on coronaviruses". World Health Organization . 11 February 2020. Retrieved 24 February 2020.
  14. 1 2 3 "Coronavirus Disease 2019 (COVID-19) - Transmission". Centers for Disease Control and Prevention. 17 March 2020. Retrieved 23 March 2020.
  15. "Q & A on COVID-19". European Centre for Disease Prevention and Control. Retrieved 23 March 2020.
  16. "New coronavirus stable for hours on surfaces". National Institutes of Health. 17 March 2020. Retrieved 23 March 2020.
  17. Velavan, T. P.; Meyer, C. G. (March 2020). "The COVID-19 epidemic". Tropical Medicine & International Health. n/a (n/a): 278–80. doi: 10.1111/tmi.13383 . PMID   32052514.
  18. 1 2 "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. 11 February 2020. Retrieved 26 March 2020.
  19. 1 2 Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. (February 2020). "A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)". Military Medical Research. 7 (1): 4. doi: 10.1186/s40779-020-0233-6 . PMC   7003341 . PMID   32029004.
  20. "CT provides best diagnosis for COVID-19". ScienceDaily. 26 February 2020. Retrieved 2 March 2020.
  21. "Advice for public". World Health Organization (WHO). Archived from the original on 26 January 2020. Retrieved 25 February 2020.
  22. "Guidance on social distancing for everyone in the UK". GOV.UK. Retrieved 25 March 2020.
  23. 1 2 CDC (11 February 2020). "2019 Novel Coronavirus (2019-nCoV)". Centers for Disease Control and Prevention. Archived from the original on 14 February 2020. Retrieved 15 February 2020.
  24. "Advice for public". World Health Organization (WHO). Archived from the original on 26 January 2020. Retrieved 15 February 2020.
  25. "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention (CDC). 15 February 2020. Archived from the original on 26 February 2020. Retrieved 20 February 2020.
  26. "Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)". World Health Organization (WHO). Archived from the original on 31 January 2020. Retrieved 11 February 2020.
  27. Mahtani, S.; Berger, M.; O'Grady, S.; Iati, M. (6 February 2020). "Hundreds of evacuees to be held on bases in California; Hong Kong and Taiwan restrict travel from mainland China". The Washington Post . Archived from the original on 7 February 2020. Retrieved 11 February 2020.
  28. "WHO Situation Report #65" (PDF). WHO. 25 March 2020.
  29. 1 2 3 Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) (PDF) (Report). World Health Organization (WHO). 16–24 February 2020. Retrieved 21 March 2020.
  30. 1 2 Palus, Shannon (27 March 2020). "The Key Stat in the NYTimes' Piece About Losing Your Sense of Smell Was Wrong". Slate Magazine. Retrieved 28 March 2020.
  31. 1 2 Iacobucci, Gareth (2020). "Sixty seconds on . . . anosmia". BMJ: m1202. doi:10.1136/bmj.m1202. ISSN   1756-1833.
  32. 1 2 Wei, Xiao-Shan; Wang, Xuan; Niu, Yi-Ran; Ye, Lin-Lin; Peng, Wen-Bei; Wang, Zi-Hao; Yang, Wei-Bing; Yang, Bo-Han; Zhang, Jian-Chu; Ma, Wan-Li; Wang, Xiao-Rong (26 February 2020). Clinical Characteristics of SARS-CoV-2 Infected Pneumonia with Diarrhea. Rochester, NY. SSRN   3546120 Check |ssrn= value (help).
  33. Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; Zhang, L. (February 2020). "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". Lancet. 395 (10223): 507–513. doi: 10.1016/S0140-6736(20)30211-7 . PMID   32007143.
  34. Hessen MT (27 January 2020). "Novel Coronavirus Information Center: Expert guidance and commentary". Elsevier Connect. Archived from the original on 30 January 2020. Retrieved 31 January 2020.
  35. "Coronavirus Disease 2019 (COVID-19)—Symptoms". Centers for Disease Control and Prevention. 20 March 2020. Retrieved 21 March 2020.
  36. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (February 2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". Lancet. 395 (10223): 497–506. doi: 10.1016/S0140-6736(20)30183-5 . PMID   31986264.
  37. Lai, Chih-Cheng; Shih, Tzu-Ping; Ko, Wen-Chien; Tang, Hung-Jen; Hsueh, Po-Ren (1 March 2020). "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges". International Journal of Antimicrobial Agents. 55 (3): 105924. doi:10.1016/j.ijantimicag.2020.105924. ISSN   0924-8579. PMID   32081636.
  38. 1 2 Zheng YY, Ma YT, Zhang JY, Xie X (March 2020). "COVID-19 and the cardiovascular system". Nature Reviews. Cardiology. doi: 10.1038/s41569-020-0360-5 . PMID   32139904.
  39. "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. 11 February 2020.
  40. World Health Organization (19 February 2020). "Coronavirus disease 2019 (COVID-19): situation report, 29". World Health Organization (WHO). hdl: 10665/331118 .
  41. "Q&A on coronaviruses (COVID-19): How long is the incubation period for COVID-19?". World Health Organization (WHO). Archived from the original on 20 January 2020. Retrieved 26 February 2020.
  42. Lauer, Stephen A.; Grantz, Kyra H.; Bi, Qifang; Jones, Forrest K.; Zheng, Qulu; Meredith, Hannah R.; Azman, Andrew S.; Reich, Nicholas G.; Lessler, Justin (10 March 2020). "The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application". Annals of Internal Medicine. doi:10.7326/M20-0504. ISSN   0003-4819. PMC   7081172 . PMID   32150748.
  43. Gorbalenya AE (11 February 2020). "Severe acute respiratory syndrome-related coronavirus—The species and its viruses, a statement of the Coronavirus Study Group". bioRxiv (preprint). doi: 10.1101/2020.02.07.937862 .
  44. "2019 Novel Coronavirus (2019-nCoV)". Centers for Disease Control and Prevention. 11 February 2020. Archived from the original on 7 March 2020. Retrieved 18 February 2020. The virus is thought to spread mainly from person-to-person ... through respiratory droplets produced when an infected person coughs or sneezes.
  45. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. (March 2020). "Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1". The New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmc2004973. PMID   32182409.
  46. 1 2 3 4 Gu, Jinyang; Han, Bing; Wang, Jian (27 February 2020). "COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission". Gastroenterology. doi:10.1053/j.gastro.2020.02.054. ISSN   0016-5085. PMID   32142785.
  47. Water Transmission and COVID-19 (CDC, accessed 19 March 2020)
  48. Letko M, Marzi A, Munster V (2020). "Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses". Nature Microbiology. 5 (4): 562–569. doi: 10.1038/s41564-020-0688-y . PMID   32094589.
  49. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (March 2020). "Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target". Intensive Care Medicine. 46 (4): 586–590. doi: 10.1007/s00134-020-05985-9 . PMC   7079879 . PMID   32125455.
  50. 1 2 3 Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. (February 2020). "High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa". International Journal of Oral Science. 12 (1): 8. doi: 10.1038/s41368-020-0074-x . PMC   7039956 . PMID   32094336.
  51. Gurwitz D (March 2020). "Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics". Drug Development Research. doi: 10.1002/ddr.21656 . PMID   32129518.
  52. Hamming, I.; Timens, W.; Bulthuis, M. L. C.; Lely, A. T.; Navis, G. J.; Goor, H. van (2004). "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis". The Journal of Pathology. 203 (2): 631–637. doi:10.1002/path.1570. ISSN   1096-9896. PMID   15141377.
  53. 1 2 Zhang, Wei; Du, Rong-Hui; Li, Bei; Zheng, Xiao-Shuang; Yang, Xing-Lou; Hu, Ben; Wang, Yan-Yi; Xiao, Geng-Fu; Yan, Bing; Shi, Zheng-Li; Zhou, Peng (1 January 2020). "Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes". Emerging Microbes & Infections. 9 (1): 386–389. doi:10.1080/22221751.2020.1729071. PMC   7048229 . PMID   32065057.
  54. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. (23 January 2020). "Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin". bioRxiv (preprint). doi: 10.1101/2020.01.22.914952 .
  55. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (17 March 2020). "The proximal origin of SARS-CoV-2". Nature Medicine : 1–3. doi:10.1038/s41591-020-0820-9 . Retrieved 18 March 2020.
  56. Berger K (12 March 2020). "The Man Who Saw the Pandemic Coming". Nautilus. Retrieved 16 March 2020.
  57. 1 2 3 4 Yanping Z, et al. (The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team) (17 February 2020). "The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)—China, 2020". China CDC Weekly. Chinese Center for Disease Control and Prevention. 2 (8): 113–122. Retrieved 18 March 2020.
  58. Heymann DL, Shindo N (February 2020). "COVID-19: what is next for public health?". Lancet. 395 (10224): 542–45. doi: 10.1016/S0140-6736(20)30374-3 . PMID   32061313.
  59. Davidson, Helen (13 March 2020). "First Covid-19 case happened in November, China government records show—report". The Guardian. Retrieved 21 March 2020.
  60. CDC (5 February 2020). "CDC Tests for 2019-nCoV". Centers for Disease Control and Prevention. Archived from the original on 14 February 2020. Retrieved 12 February 2020.
  61. "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases". World Health Organization (WHO). Retrieved 13 March 2020.
  62. "2019 Novel Coronavirus (2019-nCoV) Situation Summary". Centers for Disease Control and Prevention . 30 January 2020. Archived from the original on 26 January 2020. Retrieved 30 January 2020.
  63. "Real-Time RT-PCR Panel for Detection 2019-nCoV". Centers for Disease Control and Prevention . 29 January 2020. Archived from the original on 30 January 2020. Retrieved 1 February 2020.
  64. "Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe". GlobeNewswire News Room. 30 January 2020. Archived from the original on 31 January 2020. Retrieved 1 February 2020.
  65. Brueck H (30 January 2020). "There's only one way to know if you have the coronavirus, and it involves machines full of spit and mucus". Business Insider. Archived from the original on 1 February 2020. Retrieved 1 February 2020.
  66. "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases". Archived from the original on 21 February 2020. Retrieved 26 February 2020.
  67. Cohen J, Normile D (January 2020). "New SARS-like virus in China triggers alarm" (PDF). Science. 367 (6475): 234–35. Bibcode:2020Sci...367..234C. doi:10.1126/science.367.6475.234. PMID   31949058. Archived (PDF) from the original on 11 February 2020. Retrieved 11 February 2020.
  68. "Severe acute respiratory syndrome coronavirus 2 data hub". NCBI. Retrieved 4 March 2020.
  69. Vogel, Gretchen (2020). "New blood tests for antibodies could show true scale of coronavirus pandemic". Science. doi:10.1126/science.abb8028. ISSN   0036-8075.
  70. Pang J, Wang MX, Ang IY, Tan SH, Lewis RF, Chen JI, et al. (February 2020). "Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review". Journal of Clinical Medicine. 9 (3): 623. doi:10.3390/jcm9030623. PMID   32110875.
  71. "Coronavirus (COVID-19) Update: FDA Issues first Emergency Use Authorization for Point of Care Diagnostic" (Press release). FDA. 21 March 2020. Retrieved 22 March 2020.
  72. 1 2 Salehi, Sana; Abedi, Aidin; Balakrishnan, Sudheer; Gholamrezanezhad, Ali (14 March 2020). "Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients". American Journal of Roentgenology: 1–7. doi:10.2214/AJR.20.23034. ISSN   0361-803X. PMID   32174129.
  73. Lee, Elaine Y. P.; Ng, Ming-Yen; Khong, Pek-Lan (24 February 2020). "COVID-19 pneumonia: what has CT taught us?". The Lancet Infectious Diseases. 0 (4): 384–385. doi:10.1016/S1473-3099(20)30134-1. ISSN   1473-3099. PMID   32105641 . Retrieved 13 March 2020.
  74. "ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection". American College of Radiology. 22 March 2020.
  75. Autopsy in suspected COVID-19 cases, Hanley B et al, J Clin Pathol, PMID:32198191
  76. Wiles S (9 March 2020). "The three phases of Covid-19 – and how we can make it manageable". The Spinoff. Retrieved 9 March 2020.
  77. 1 2 3 Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD (March 2020). "How will country-based mitigation measures influence the course of the COVID-19 epidemic?". Lancet. 395 (10228): 931–934. doi: 10.1016/S0140-6736(20)30567-5 . PMID   32164834. A key issue for epidemiologists is helping policy makers decide the main objectives of mitigation—e.g. minimising morbidity and associated mortality, avoiding an epidemic peak that overwhelms health-care services, keeping the effects on the economy within manageable levels, and flattening the epidemic curve to wait for vaccine development and manufacture on scale and antiviral drug therapies.
  78. Barclay E (10 March 2020). "How canceled events and self-quarantines save lives, in one chart". Vox.
  79. Wiles, Siouxsie (14 March 2020). "After 'Flatten the Curve', we must now 'Stop the Spread'. Here's what that means". The Spinoff. Retrieved 13 March 2020.
  80. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD (March 2020). "How will country-based mitigation measures influence the course of the COVID-19 epidemic?". Lancet. 395 (10228): 931–934. doi:10.1016/S0140-6736(20)30567-5. PMID   32164834.
  81. 1 2 3 4 Centers for Disease Control (3 February 2020). "Coronavirus Disease 2019 (COVID-19): Prevention & Treatment". Archived from the original on 15 December 2019. Retrieved 10 February 2020.
  82. World Health Organization. "Advice for Public". Archived from the original on 26 January 2020. Retrieved 10 February 2020.
  83. "My Hand-Washing Song: Readers Offer Lyrics For A 20-Second Scrub". Retrieved 20 March 2020.
  84. Maragakis LL. "Coronavirus, Social Distancing and Self Quarantine". John Hopkins University.
  85. Parker-Pope, Tara (19 March 2020). "Deciding How Much Distance You Should Keep". The New York Times. ISSN   0362-4331 . Retrieved 20 March 2020.
  86. Grenfell R, Drew T (17 February 2020). "Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus". Science Alert. Archived from the original on 28 February 2020. Retrieved 26 February 2020.
  87. "When and how to use masks". World Health Organization (WHO). Retrieved 8 March 2020.
  88. "For different groups of people: how to choose masks". National Health Commission of the People's Republic of China. 7 February 2020. Retrieved 22 March 2020. Disposable medical masks: Recommended for: · People in crowded places · Indoor working environment with a relatively dense population · People going to medical institutions · Children in kindergarten and students at school gathering to study and do other activities
  89. "Prevention of Coronavirus Disease 2019 (COVID-19)" (PDF). Centre for Health Protection . Retrieved 22 March 2020. Wear a surgical mask when taking public transport or staying in crowded places.
  90. Kuhakan, Jiraporn (12 March 2020). "'Better than nothing': Thailand encourages cloth masks amid surgical mask shortage". Reuters. Thailand's health authorities are encouraging people to make cloth face masks at home to guard against the spread of the coronavirus amid a shortage of surgical masks. ... The droplet from coughing and sneezing is around five microns and we have tested already that cloth masks can protect against droplets bigger than one micron.
  91. "Shortage of personal protective equipment endangering health workers worldwide" (Press release). WHO. 3 March 2020. Retrieved 24 March 2020.
  92. "Guidance against wearing masks for the coronavirus is wrong – you should cover your face - The Boston Globe".
  93. "Coronavirus Disease 2019 (COVID-19)—Prevention & Treatment". Centers for Disease Control and Prevention. U.S. Department of Health & Human Services. 10 March 2020.
  94. Centers for Disease Control and Prevention (11 February 2020). "What to do if you are sick with 2019 Novel Coronavirus (2019-nCoV)". Archived from the original on 14 February 2020. Retrieved 13 February 2020.
  95. "WHO-recommended handrub formulations". WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. World Health Organization. 19 March 2009. Retrieved 19 March 2020.
  96. "Sequence for Putting On Personal Protective Equipment (PPE)" (PDF). CDC. Retrieved 8 March 2020.
  97. 1 2 Fisher D, Heymann D (February 2020). "Q&A: The novel coronavirus outbreak causing COVID-19". BMC Medicine. 18 (1): 57. doi: 10.1186/s12916-020-01533-w . PMC   7047369 . PMID   32106852.
  98. Kui L, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. (February 2020). "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province". Chinese Medical Journal: 1. doi: 10.1097/CM9.0000000000000744 . PMID   32044814.
  99. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B (March 2020). "Comorbidities and multi-organ injuries in the treatment of COVID-19". Lancet. Elsevier BV. 395 (10228): e52. doi:10.1016/s0140-6736(20)30558-4. PMID   32171074.
  100. 1 2 Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. (February 2020). "Clinical Characteristics of Coronavirus Disease 2019 in China". The New England Journal of Medicine. Massachusetts Medical Society. doi: 10.1056/nejmoa2002032 . PMID   32109013.
  101. Henry BM (2020). "COVID-19, ECMO, and lymphopenia: a word of caution". The Lancet Respiratory Medicine. Elsevier BV. doi:10.1016/s2213-2600(20)30119-3. ISSN   2213-2600. PMID   32178774.
  102. Cheng ZJ, Shan J (February 2020). "2019 Novel coronavirus: where we are and what we know". Infection. 48 (2): 155–163. doi: 10.1007/s15010-020-01401-y . PMID   32072569.
  103. "Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected". World Health Organization (WHO). Archived from the original on 31 January 2020. Retrieved 13 February 2020.
  104. Farkas J (March 2020). COVID-19—The Internet Book of Critical Care (digital) (Reference manual). USA: EMCrit. Archived from the original on 11 March 2020. Retrieved 13 March 2020.
  105. "COVID19—Resources for Health Care Professionals". Penn Libraries. 11 March 2020. Retrieved 13 March 2020.
  106. AFP (19 March 2020). "Updated: WHO Now Doesn't Recommend Avoiding Ibuprofen For COVID-19 Symptoms". ScienceAlert. Retrieved 19 March 2020.
  107. Day, Michael (17 March 2020). "Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists". BMJ. 368: m1086. doi:10.1136/bmj.m1086. PMID   32184201 . Retrieved 18 March 2020.
  108. "Self-isolation advice - Coronavirus (COVID-19)". National Health Service (United Kingdom). 28 February 2020. Retrieved 27 March 2020.
  109. Day, Michael (17 March 2020). "Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists". BMJ. 368: m1086. doi:10.1136/bmj.m1086. ISSN   1756-1833. PMID   32184201.
  110. Research, Center for Drug Evaluation and (19 March 2020). "FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19". Drug Safety and Availability.
  111. "Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician" . Retrieved 21 March 2020.
  112. "Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician". American Heart Association (Press release). 17 March 2020. Retrieved 25 March 2020.
  113. de Simone, Giovanni. "Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers". Council on Hypertension of the European Society of Cardiology. Retrieved 24 March 2020.
  114. Vetter P, Eckerle I, Kaiser L (February 2020). "Covid-19: a puzzle with many missing pieces". BMJ. 368: m627. doi: 10.1136/bmj.m627 . PMID   32075791.
  115. "Novel Coronavirus—COVID-19: What Emergency Clinicians Need to Know". Retrieved 9 March 2020.
  116. Cheung JC, Ho LT, Cheng JV, Cham EY, Lam KN (February 2020). "Staff safety during emergency airway management for COVID-19 in Hong Kong". Lancet Respiratory Medicine. doi: 10.1016/s2213-2600(20)30084-9 . PMID   32105633.
  117. Filtering out Confusion: Frequently Asked Questions about Respiratory Protection, User Seal Check. The National Institute for Occupational Safety and Health (April 2018). Retrieved 16 March 2020.
  118. Proper N95 Respirator Use for Respiratory Protection Preparedness. NIOSH Science Blog (16 March 2020). Retrieved 16 March 2020.
  119. "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. 11 February 2020. Retrieved 11 March 2020.
  120. "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. 11 February 2020. Retrieved 8 March 2020.
  121. "Strategies for Optimizing the Supply of Eye Protection". CDC. 11 February 2020.
  122. CDC (11 February 2020). "Interim Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed Coronavirus Disease 2019 (COVID-19) in Healthcare Settings". Centers for Disease Control and Prevention. Retrieved 25 March 2020.
  123. "Coronavirus Disease 2019 (COVID-19) Frequently Asked Questions". Food and Drug Administration.
  124. "Strategies for Optimizing the Supply of Facemasks". CDC. 11 February 2020.
  125. 1 2 3 Murthy S, Gomersall CD, Fowler RA (11 March 2020). "Care for Critically Ill Patients With COVID-19". JAMA. doi:10.1001/jama.2020.3633. PMID   32159735.
  126. World Health Organization (28 January 2020). "Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected" (PDF).
  127. Ferguson, N.; Laydon, D.; Nedjati Gilani, G.; Imai, N.; Ainslie, K.; Baguelin, M.; Bhatia, S.; Boonyasiri, A.; Cucunuba Perez, Zulma; Cuomo-Dannenburg, G.; Dighe, A. (16 March 2020). "Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand". Imperial College London. Table 1. doi: 10.25561/77482 . hdl:20.1000/100.Cite journal requires |journal= (help)
  128. 1 2 Scott, Dylan (16 March 2020). "Coronavirus is exposing all of the weaknesses in the US health system High health care costs and low medical capacity made the US uniquely vulnerable to the coronavirus". Vox. Retrieved 18 March 2020.
  130. "[Updating] Italian hospital saves Covid-19 patients lives by 3D printing valves for reanimation devices". 3D Printing Media Network. 14 March 2020. Retrieved 20 March 2020.
  131. 1 2 Matthay, Michael A.; Aldrich, J. Matthew; Gotts, Jeffrey E. (March 2020). "Treatment for severe acute respiratory distress syndrome from COVID-19". The Lancet Respiratory Medicine. doi:10.1016/S2213-2600(20)30127-2. PMID   32203709.
  132. Briel, Matthias; Meade, Maureen; Mercat, Alain; Brower, Roy G.; Talmor, Daniel; Walter, Stephen D.; Slutsky, Arthur S.; Pullenayegum, Eleanor; Zhou, Qi; Cook, Deborah; Brochard, Laurent; Richard, Jean-Christophe M.; Lamontagne, Francois; Bhatnagar, Neera; Stewart, Thomas E.; Guyatt, Gordon (3 March 2010). "Higher vs Lower Positive End-Expiratory Pressure in Patients With Acute Lung Injury and Acute Respiratory Distress Syndrome". JAMA. 303 (9): 865–73. doi:10.1001/jama.2010.218. PMID   20197533.
  133. Diaz, Raiko; Heller, Daniel (2020). Barotrauma And Mechanical Ventilation. StatPearls. StatPearls Publishing. PMID   31424810.
  134. 1 2 3 4 Li G, De Clercq E (March 2020). "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)". Nature Reviews. Drug Discovery. 19 (3): 149–150. doi: 10.1038/d41573-020-00016-0 . PMID   32127666.
  135. "Chinese doctors using plasma therapy on coronavirus, WHO says 'very valid' approach". Reuters. 17 February 2020 via
  136. Steenhuysen J, Kelland K (24 January 2020). "With Wuhan virus genetic code in hand, scientists begin work on a vaccine". Reuters. Archived from the original on 25 January 2020. Retrieved 25 January 2020.
  137. Duddu P (19 February 2020). "Coronavirus outbreak: Vaccines/drugs in the pipeline for Covid-19". Archived from the original on 19 February 2020.
  138. Lu H (28 January 2020). "Drug treatment options for the 2019-new coronavirus (2019-nCoV)". Biosci Trends. 14 (1): 69–71. doi:10.5582/bst.2020.01020. PMID   31996494.
  139. Nebehay S, Kelland K, Liu R (5 February 2020). "WHO: 'no known effective' treatments for new coronavirus". Thomson Reuters. Archived from the original on 5 February 2020. Retrieved 5 February 2020.
  140. "China launches coronavirus 'close contact' app". BBC News. 11 February 2020. Retrieved 7 March 2020.
  141. Chen A. "China's coronavirus app could have unintended consequences". MIT Technology Review. Retrieved 7 March 2020.
  142. "Gov in the Time of Corona". GovInsider. 19 March 2020. Retrieved 20 March 2020.
  143. Manancourt, Vincent (10 March 2020). "Coronavirus tests Europe's resolve on privacy". POLITICO. Retrieved 20 March 2020.
  144. Tidy, Joe (17 March 2020). "Coronavirus: Israel enables emergency spy powers". BBC News. Retrieved 18 March 2020.
  145. Bünte, Oliver (18 March 2020). "Corona-Krise: Deutsche Telekom liefert anonymisierte Handydaten an RKI" [Corona crisis: Deutsche Telekom delivers anonymized cell phone data to RKI]. Heise Online (in German). Retrieved 25 March 2020.
  146. "Moscow deploys facial recognition technology for coronavirus quarantine". Reuters. 21 February 2020. Retrieved 20 March 2020.
  147. "Italians scolded for flouting lockdown as death toll nears 3,000". Pittsburgh Post-Gazette. Retrieved 20 March 2020.
  148. "Kreative Lösungen gesucht". Startseite (in German).
  149. Dannewitz, Juliane (23 March 2020). "Hackathon Germany: #WirvsVirus". Datenschutzbeauftragter (in German).
  150. Whyte, Andrew (21 March 2020). "President makes global call to combat coronavirus via hackathon". ERR.
  151. Xiang YT, Yang Y, Li W, Zhang L, Zhang Q, Cheung T, et al. (March 2020). "Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed". The Lancet. Psychiatry. 7 (3): 228–29. doi: 10.1016/S2215-0366(20)30046-8 . PMID   32032543.
  152. Kang L, Li Y, Hu S, Chen M, Yang C, Yang BX, et al. (March 2020). "The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus". The Lancet. Psychiatry. 7 (3): e14. doi: 10.1016/S2215-0366(20)30047-X . PMID   32035030.
  153. Roser M, Ritchie H, Ortiz-Ospina E (4 March 2020). "Coronavirus Disease (COVID-19)". Our World in Data. Retrieved 12 March 2020.
  154. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. (18 March 2020). "SARS-CoV-2 Infection in Children". New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmc2005073. ISSN   0028-4793. PMID   32187458.
  155. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S (2020). "Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China" (PDF). Pediatrics: e20200702. doi:10.1542/peds.2020-0702. PMID   32179660.
  156. Fang L, Karakiulakis G, Roth M (March 2020). "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?". The Lancet Respiratory Medicine . 395 (10224): e40. doi:10.1016/S0140-6736(20)30311-1. PMID   32171062.
  157. "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. 11 February 2020. Retrieved 2 March 2020.
  158. Heymann DL, Shindo N, et al. (WHO Scientific and Technical Advisory Group for Infectious Hazards) (February 2020). "COVID-19: what is next for public health?". Lancet. Elsevier BV. 395 (10224): 542–545. doi:10.1016/s0140-6736(20)30374-3. PMID   32061313.
  159. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020). "Features, Evaluation and Treatment Coronavirus (COVID-19)". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   32150360 . Retrieved 18 March 2020.
  160. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. (2020). "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study". The Lancet. Elsevier BV. 395 (10229): 1054–1062. doi:10.1016/s0140-6736(20)30566-3. ISSN   0140-6736. PMID   32171076.
  161. Xu L, Liu J, Lu M, Yang D, Zheng X (March 2020). "Liver injury during highly pathogenic human coronavirus infections". Liver International. doi:10.1111/liv.14435. PMID   32170806.
  162. Tian, Dai-Shi; Wang, Wei; Shang, Ke; Ma, Ke; Xie, Cuihong; Tao, Yu; Yang, Sheng; Zhang, Shuoqi; Hu, Ziwei; Zhou, Luoqi; Qin, Chuan (12 March 2020). "Dysregulation of immune response in patients with COVID-19 in Wuhan, China". Clinical Infectious Diseases. doi:10.1093/cid/ciaa248. PMID   32161940.
  163. "WHO Director-General's statement on the advice of the IHR Emergency Committee on Novel Coronavirus". World Health Organization (WHO).
  164. 1 2 Epidemia COVID-19. Aggiornamento nazionale 26 marzo 2020 (PDF) (Report) (in Italian). Rome: Istituto Superiore di Sanità. 27 March 2020. Retrieved 27 March 2020.
  165. 1 2 Palmieri L, Andrianou X, Barbariol P, Bella A, Bellino S, Benelli E, Bertinato L, Boros S, Brambilla G, Calcagnini G, Canevelli M, Castrucci MR, Censi F, Ciervo A, Colaizzo E, D'Ancona F, Del Manso M, Donfrancesco C, Fabiani M, Filia A, Grisetti T, Langer M, Lega I, Lo Noce C, Maiozzi P, Manno V, Martini M, Mateo Urdiales A, Mattei E, Meduri C, Minelli G, Nebuloni M, Nisticò L, Nonis M, Onder G, Petrosillo N, Pezzotti P, Punzo O, Raparelli V, Rezza G, Riccardo F, Rota MC, Serra D, Siddu A, Stefanelli P, Tiple D, Unim B, Vaianella L, Vanacore N, Vichi M, Brusaferro S (27 March 2020). Characteristics of COVID-19 patients dying in Italy (PDF) (Report). Istituto Superiore di Sanità . Retrieved 27 March 2020.
  166. Wang W, Tang J, Wei F (April 2020). "Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China". Journal of Medical Virology. 92 (4): 441–47. doi: 10.1002/jmv.25689 . PMID   31994742.
  167. "Coronavirus Age, Sex, Demographics (COVID-19)". Archived from the original on 27 February 2020. Retrieved 26 February 2020.
  168. Ji Y, Ma Z, Peppelenbosch MP, Pan Q (February 2020). "Potential association between COVID-19 mortality and health-care resource availability". Lancet Global Health. 8 (4): e480. doi: 10.1016/S2214-109X(20)30068-1 . PMID   32109372.
  169. Li XQ, Cai WF, Huang LF, Chen C, Liu YF, Zhang ZB, et al. (March 2020). "[Comparison of epidemic characteristics between SARS in2003 and COVID-19 in 2020 in Guangzhou]". Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi (in Chinese). 41 (5): 634–637. doi:10.3760/cma.j.cn112338-20200228-00209. PMID   32159317.
  170. Jung SM, Akhmetzhanov AR, Hayashi K, Linton NM, Yang Y, Yuan B, et al. (February 2020). "Real-Time Estimation of the Risk of Death from Novel Coronavirus (COVID-19) Infection: Inference Using Exported Cases". Journal of Clinical Medicine. 9 (2): 523. doi:10.3390/jcm9020523. PMC   7074479 . PMID   32075152.
  171. Chughtai A, Malik A (March 2020). "Is Coronavirus disease (COVID-19) case fatality ratio underestimated?". Global Biosecurity. 1 (3). doi:10.31646/gbio.56 (inactive 19 March 2020).
  172. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G (March 2020). "Real estimates of mortality following COVID-19 infection". The Lancet Infectious Diseases. doi:10.1016/S1473-3099(20)30195-X. PMID   32171390.
  173. "BSI open letter to Government on SARS-CoV-2 outbreak response | British Society for Immunology". Retrieved 15 March 2020.
  174. "Can you get coronavirus twice or does it cause immunity?". The Independent. 13 March 2020. Retrieved 15 March 2020.
  175. "They survived the coronavirus. Then they tested positive again. Why?". Los Angeles Times. 13 March 2020. Retrieved 15 March 2020.
  176. "14% of Recovered Covid-19 Patients in Guangdong Tested Positive Again—Caixin Global". Retrieved 15 March 2020.
  177. Cheung E (13 March 2020). "Some recovered Covid-19 patients may have lung damage, doctors say". South China Morning Post .
  178. Epidemiologische situatie COVID-19 in Nederland 27 maart 2020 (PDF) (Report) (in Dutch). Bilthoven: Rijksinstituut voor Volksgezondheid en Milie. 27 March 2020. Retrieved 27 March 2020.
  179. 코로나바이러스감염증-19 국내 발생 현황(3월 27일, 정례브리핑) (PDF) (Report) (in Korean). Korea Centers for Disease Control and Prevention. 27 March 2020. Retrieved 27 March 2020.
  180. Actualización nº 57. Enfermedad por el coronavirus (COVID-19) (PDF) (Report) (in Spanish). Ministerio de Sanidad, Consumo y Bienestar Social. 27 March 2020. Retrieved 27 March 2020.
  181. CDC COVID-19 Response Team (18 March 2020). "Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020". Morbidity and Mortality Weekly Report . Centers for Disease Control. 69 (12): 343–346. doi:10.15585/mmwr.mm6912e2. PMID   32214079 . Retrieved 22 March 2020.
  182. "Coronavirus causes mild disease in four in five patients, says WHO". Journal of Clinical Medicine. 15 February 2020. Retrieved 26 March 2020.
  183. "Limited data on coronavirus may be skewing assumptions about severity". STAT . 30 January 2020. Archived from the original on 1 February 2020. Retrieved 1 February 2020.
  184. Sparrow A. "How China's Coronavirus Is Spreading—and How to Stop It". Foreign Policy . Archived from the original on 31 January 2020. Retrieved 2 February 2020.
  185. "WHOが"致死率3%程度" 専門家「今後 注意が必要」". NHK. 24 January 2020. Archived from the original on 26 January 2020. Retrieved 3 February 2020.
  186. Boseley S (17 February 2020). "Coronavirus causes mild disease in four in five patients, says WHO". The Guardian. Archived from the original on 18 February 2020. Retrieved 18 February 2020.
  187. Diao Y, Liu X, Wang T, Zeng X, Dong C, Zhou C, Zhang Y, She X, Liu D, Hu Z (20 February 2020). "Estimating the cure rate and case fatality rate of the ongoing epidemic COVID-19". MedRxiv (preprint). doi: 10.1101/2020.02.18.20024513 .
  188. "2019-nCoV: preliminary estimates of the confirmed-case-fatality-ratio and infection-fatality-ratio, and initial pandemic risk assessment". Retrieved 1 March 2020.
  189. "Report 4: Severity of 2019-novel coronavirus (nCoV)" (PDF). Archived (PDF) from the original on 10 February 2020. Retrieved 10 February 2020.
  190. Wu, Joseph T.; Leung, Kathy; Bushman, Mary; Kishore, Nishant; Niehus, Rene; de Salazar, Pablo M.; Cowling, Benjamin J.; Lipsitch, Marc; Leung, Gabriel M. (19 March 2020). "Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China". Nature Medicine: 1–5. doi:10.1038/s41591-020-0822-7 via
  191. "Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE". ArcGIS. Johns Hopkins CSSE. Retrieved 28 March 2020.
  192. Kucharski, Adam J; Russell, Timothy W; Diamond, Charlie; Liu, Yang; Edmunds, John; Funk, Sebastian; Eggo, Rosalind M; Sun, Fiona; Jit, Mark; Munday, James D; Davies, Nicholas; Gimma, Amy; van Zandvoort, Kevin; Gibbs, Hamish; Hellewell, Joel; Jarvis, Christopher I; Clifford, Sam; Quilty, Billy J; Bosse, Nikos I; Abbott, Sam; Klepac, Petra; Flasche, Stefan (March 2020). "Early dynamics of transmission and control of COVID-19: a mathematical modelling study". The Lancet Infectious Diseases. doi:10.1016/S1473-3099(20)30144-4. PMID   32171059.
  193. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. (February 2020). "Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records". Lancet. 395 (10226): 809–15. doi: 10.1016/S0140-6736(20)30360-3 . PMID   32151335.
  194. Cui P, Chen Z, Wang T, Dai J, Zhang J, Ding T, Jiang J, Liu J, Zhang C, Shan W, Wang S, Rong Y, Chang J, Miao X, Ma X, Wang S (27 February 2020). "Clinical features and sexual transmission potential of SARS-CoV-2 infected female patients: a descriptive study in Wuhan, China". MedRxiv (preprint). doi: 10.1101/2020.02.26.20028225 .
  195. "Total confirmed cases of COVID-19 per million people". Our World in Data. Retrieved 20 March 2020.
  196. "Total confirmed deaths due to COVID-19 per million people". Our World in Data. Retrieved 24 March 2020.
  197. "Novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – sixth update" (PDF). ecdc. Retrieved 26 March 2020.
  198. "Novel coronavirus named 'Covid-19': WHO". TODAYonline. Retrieved 11 February 2020.
  199. "The coronavirus spreads racism against—and among—ethnic Chinese". The Economist . 17 February 2020. Archived from the original on 17 February 2020. Retrieved 17 February 2020.
  200. 1 2 "Naming the coronavirus disease (COVID-19) and the virus that causes it". World Health Organization (WHO). Retrieved 13 March 2020.
  201. "Novel Coronavirus(2019-nCoV) Situation Report—10" (PDF). World Health Organization (WHO). 30 January 2020. Retrieved 15 March 2020.
  202. "Virology: Coronaviruses". Nature. 220 (5168): 650. 1968. Bibcode:1968Natur.220..650.. doi:10.1038/220650b0. ISSN   0028-0836.
  203. Definition of Coronavirus by Merriam-Webster, Merriam-Webster, retrieved 24 March 2020
  204. Definition of Corona by Merriam-Webster, Merriam-Webster, retrieved 24 March 2020
  209. "Trump doubles down on 'China virus,' demands to know who in White House used phrase 'Kung Flu"". Fox News. 18 March 2020. Retrieved 18 March 2020.
  210. "A last, desperate pivot: Trump and his allies go full racist on coronavirus". Salon. 19 March 2020. Retrieved 19 March 2020.
  211. Wang, Li-sheng; Wang, Yi-ru; Ye, Da-wei; Liu, Qing-quan (19 March 2020). "A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence". International Journal of Antimicrobial Agents: 105948. doi:10.1016/j.ijantimicag.2020.105948. ISSN   0924-8579. PMID   32201353 . Retrieved 27 March 2020.
  212. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (March 2020). "Features, Evaluation and Treatment Coronavirus (COVID-19)". StatPearls [Internet]. PMID   32150360. Bookshelf ID: NBK554776.
  213. Chen WH, Strych U, Hotez PJ, Bottazzi ME (3 March 2020). "The SARS-CoV-2 Vaccine Pipeline: an Overview". Current Tropical Medicine Reports. doi: 10.1007/s40475-020-00201-6 .
  214. Roberts M (17 March 2020). "Coronavirus: US volunteers test first vaccine". BBC News. Retrieved 17 March 2020.
  215. Kupferschmidt, Kai; Cohen, Jon (22 March 2020). "WHO launches global megatrial of the four most promising coronavirus treatments". Science | AAAS. Retrieved 23 March 2020.
  216. "UN health chief announces global 'solidarity trial' to jumpstart search for COVID-19 treatment". UN News. 18 March 2020. Retrieved 23 March 2020.
  217. Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PI, Hsueh PR (March 2020). "Arguments in favor of remdesivir for treating SARS-CoV-2 infections". International Journal of Antimicrobial Agents: 105933. doi: 10.1016/j.ijantimicag.2020.105933 . PMID   32147516.
  218. 1 2 Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. (February 2020). "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro". Cell Research. 30 (3): 269–71. doi: 10.1038/s41422-020-0282-0 . PMC   7054408 . PMID   32020029.
  219. Beeching NJ, Fletcher TE, Fowler R (2020). "BMJ Best Practices: COVID-19" (PDF). BMJ.
  220. "AIFA e Gilead annunciano che l'Italia è tra i Paesi che testeranno l'antivirale remdesivir per il trattamento del COVID-19". (in Italian). Retrieved 19 March 2020.
  221. Gao J, Tian Z, Yang X (February 2020). "Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies". Bioscience Trends. 14 (1): 72–73. doi: 10.5582/bst.2020.01047 . PMID   32074550.
  222. Touret F, de Lamballerie X (March 2020). "Of chloroquine and COVID-19". Antiviral Research. 177: 104762. doi:10.1016/j.antiviral.2020.104762. PMID   32147496.
  223. multicenter collaboration group of Department of Science Technology of Guangdong Province Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia (February 2020). "[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]". Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases. 43: E019. doi:10.3760/cma.j.issn.1001-0939.2020.0019. PMID   32075365.
  224. 1 2 "Azioni intraprese per favorire la ricerca e l'accesso ai nuovi farmaci per il trattamento del COVID-19". (in Italian). Retrieved 18 March 2020.
  225. "Physicians work out treatment guidelines for coronavirus". (in Korean). 13 February 2020.
  226. 1 2 "Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 7th Edition)". China Law Translate. 4 March 2020.
  227. "Malaria drug touted as coronavirus treatment by Trump and Elon Musk can be deadly, China finds". Fortune. Retrieved 23 March 2020.
  228. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. (March 2020). "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19". The New England Journal of Medicine. doi:10.1056/NEJMoa2001282. PMID   32187464.
  229. 1 2 Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S (31 January 2020). "The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells". bioRxiv (preprint). doi: 10.1101/2020.01.31.929042 .
  230. Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, Takeda M, Nagata N (March 2019). "TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection". Journal of Virology. 93 (6). doi: 10.1128/JVI.01815-18 . PMC   6401451 . PMID   30626688.
  231. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery 2020 Feb doi : 10.1038/d41573-020-00016-0
  232. BRIEF-Corrected-Zhejiang Hisun Pharma gets approval for clinical trial to test flu drug Favipiravir for pneumonia caused by new coronavirus. Reuters Healthcare, 16 February 2020.
  233. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D (March 2020). "In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)". Clin. Infect. Dis. doi:10.1093/cid/ciaa237. PMID   32150618.
  234. Liu R, Miller J (3 March 2020). "China approves use of Roche drug in battle against coronavirus complications". Reuters . Retrieved 14 March 2020.
  235. "Effective Treatment of Severe COVID-19 Patients with Tocilizumab". 5 March 2020. doi:10.12074/202003.00026 (inactive 16 March 2020). Retrieved 14 March 2020.Cite journal requires |journal= (help)
  236. "3 patients get better on arthritis drug". 5 March 2020. Retrieved 14 March 2020.
  237. "Coronavirus, via libera dell'Aifa al farmaco anti-artrite efficace su 3 pazienti e a un antivirale: test in 5 centri" [Coronavirus, Aifa gives go-ahead to effective anti-arthritis drug on 3 patients and an antiviral: test in 5 centers]. Il Messaggero (in Italian). Retrieved 14 March 2020.
  238. "How doctors can potentially significantly reduce the number of deaths from Covid-19". Vox. 12 March 2020. Retrieved 14 March 2020.
  239. Ruan Q, Yang K, Wang W, Jiang L, Song J (March 2020). "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China". Intensive Care Medicine. doi:10.1007/s00134-020-05991-x. PMC   7080116 . PMID   32125452.
  240. Mehta P, McAuley DF, Brown M, et al. (16 March 2020). "COVID-19: consider cytokine storm syndromes and immunosuppression". The Lancet . 395 (10229): 1033–1034. doi:10.1016/S0140-6736(20)30628-0. PMID   32192578 . Retrieved 19 March 2020.
  241. "China turns Roche arthritis drug Actemra against COVID-19 in new treatment guidelines". FiercePharma. Retrieved 14 March 2020.
  242. "Northwell Health Initiates Clinical Trials of 2 COVID-19 Drugs". 21 March 2020.
  243. 1 2 3 4 Casadevall A, Pirofski LA (March 2020). "The convalescent sera option for containing COVID-19". The Journal of Clinical Investigation. doi:10.1172/JCI138003. PMID   32167489.
  244. Pearce K (13 March 2020). "Antibodies from COVID-19 survivors could be used to treat patients, protect those at risk: Infusions of antibody-laden blood have been used with reported success in prior outbreaks, including the SARS epidemic and the 1918 flu pandemic". The Hub at Johns Hopkins University. Retrieved 14 March 2020.

Further reading

Health agencies:


Medical journals: